Martin Feldman, DO
Family Medicine · Phoenix, AZNPI 1740272921
Payments from drug & device makers
Across 66 payments — averaging $19.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$100
- Novo Nordisk$93
- Amgen$93
- Pfizer$86
- Astellas Pharma US Inc$85
- GSK$84
- plus $730 from 20 others
What the payments were for
- Food & beverage$1,271100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 6 | $100 |
| Novo Nordisk | 5 | $93 |
| Amgen | 4 | $93 |
| Pfizer | 6 | $86 |
| Astellas Pharma US Inc | 4 | $85 |
| GSK | 5 | $84 |
| Edwards Lifesciences | 2 | $73 |
| Abiomed | 1 | $71 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $63 |
| AbbVie(2 entities) | 3 | $60 |
| Abbott | 3 | $55 |
| Boston Scientific | 2 | $46 |
| Boehringer Ingelheim | 2 | $45 |
| Impel Pharmaceuticals Inc. | 2 | $43 |
| Nevro Corp. | 2 | $40 |
| AstraZeneca | 3 | $35 |
| Medtronic(2 entities) | 2 | $34 |
| Johnson & Johnson | 2 | $30 |
| Phadia US Inc. | 1 | $24 |
| VBI Vaccine (delaware) Inc. | 1 | $20 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $18 |
| Merck | 1 | $17 |
| Ultragenyx Pharmaceutical Inc. | 1 | $16 |
| Sanofi Pasteur Inc. | 1 | $13 |
| Bausch Health US, LLC | 1 | $13 |
| Amarin Pharma, Inc. | 1 | $12 |
How this compares
$1,271 in reported general payments places this provider in the 70th percentile of 2,099 family medicine providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Atorvastatin Calcium | 73 | $652 |
| Omeprazole | 22 | $597 |
| Losartan Potassium | 48 | $568 |
| Gabapentin | 16 | $415 |
| Famotidine | 18 | $371 |
| Rosuvastatin Calcium | 23 | $361 |
| Carvedilol | 17 | $338 |
| Levothyroxine Sodium | 30 | $326 |
| Allopurinol | 12 | $325 |
| Lisinopril | 45 | $309 |
| Amlodipine Besylate | 48 | $245 |
| Fluticasone Propionate | 12 | $222 |
| Metformin Hcl | 33 | $216 |
| Pantoprazole Sodium | 18 | $210 |
| Simvastatin | 28 | $205 |
Paid to pharmacies, not to this prescriber.
Other family medicine in Phoenix
- Brock MerrittPhoenix$8.4M
- Douglas CunninghamPhoenix$4.9M
- Jeffrey ZacherPhoenix$2M
- Trisha TavaresPhoenix$1.6M
- David FrancykPhoenix$1.3M
- James BeachPhoenix$1.2M
- Peter LevinsPhoenix$971K
- Elysa ShawPhoenix$774K
- Mitchell EdelsteinPhoenix$741K
- Brian DedinskyPhoenix$589K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.